Upstream Bio, Inc. (UPB)
NMS · Healthcare · Biotechnology
$6.10
-4.39%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$450.6M
P/S (TTM)
136x
Exchange
NMS
About Upstream Bio, Inc.
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 937K | 683K | 668K | 1.0M |
| Operating Income | -44.3M | -37.8M | -46.2M | -43.6M |
| Net Income | -40.0M | -33.7M | -42.5M | -40.6M |
| Diluted EPS | $-0.74 | $-0.63 | $-0.78 | $-0.75 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 1.2M | 2.4M | 2.4M | 2.9M |
| Operating Income | -23.9M | -40.1M | -77.8M | -160.4M |
| Net Income | -23.9M | -20.5M | -62.8M | -143.4M |
| Diluted EPS | $-0.66 | $-1.05 | $-1.17 | $-2.66 |